• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease.

作者信息

Roccatello Dario

出版信息

Autoimmun Rev. 2013 Jun;12(8):793-5. doi: 10.1016/j.autrev.2012.11.002. Epub 2012 Dec 4.

DOI:10.1016/j.autrev.2012.11.002
PMID:23219772
Abstract
摘要

相似文献

1
Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease.生物药物时代免疫介导性和罕见病的新型诊断方法及治疗的成本效益平衡：来自第15届都灵免疫病理学与罕见病大会的经验教训
Autoimmun Rev. 2013 Jun;12(8):793-5. doi: 10.1016/j.autrev.2012.11.002. Epub 2012 Dec 4.
2
Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers.评估和定价罕见病药物：没有简单的答案。
Value Health. 2018 May;21(5):547-552. doi: 10.1016/j.jval.2018.01.008.
3
Competing for public funding of medicines to treat rare disorders in New Zealand.争夺新西兰治疗罕见疾病药物的公共资金。
Bull World Health Organ. 2015 Feb 1;93(2):67. doi: 10.2471/BLT.14.148189.
4
Limits on use of health economic assessments for rare diseases.罕见病卫生经济评估的使用限制。
QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22.
5
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?罕见肺部疾病与孤儿药：我们现状如何，又将何去何从？
Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015.
6
Rare diseases and effective treatments: are we delivering?罕见病与有效治疗：我们做到了吗？
Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5.
7
How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?如何监测罕见的、治疗难治性免疫介导炎症性疾病中生物治疗的安全性和有效性？
Rheumatology (Oxford). 2018 Apr 1;57(4):591-593. doi: 10.1093/rheumatology/kex016.
8
[Medicoeconomic data on rare disease drugs: a move towards more transparency?].[罕见病药物的药物经济学数据：朝着更高透明度迈进？]
Presse Med. 2012 May;41 Suppl 1:S57-64. doi: 10.1016/j.lpm.2012.02.024. Epub 2012 Apr 8.
9
Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.罕见病药物的报销价格：当前策略与潜在改进
Public Health Genomics. 2017;20(1):1-8. doi: 10.1159/000464100. Epub 2017 Mar 31.
10
Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.罕见病：应对诊断、药物审批及患者就医方面的挑战
Value Health. 2018 May;21(5):491-492. doi: 10.1016/j.jval.2018.03.009. Epub 2018 Apr 10.

引用本文的文献

1
Unique topics and issues in rheumatology and clinical immunology.风湿病学和临床免疫学中的独特主题和问题。
Clin Rev Allergy Immunol. 2014 Aug;47(1):1-5. doi: 10.1007/s12016-014-8441-z.
2
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.与用于治疗系统性红斑狼疮的免疫抑制剂药物相关的不良事件负担、资源利用及成本：一项系统文献综述
Int J Rheumatol. 2013;2013:347520. doi: 10.1155/2013/347520. Epub 2013 Apr 3.